Document:

AGREEMENT
BY AND BETWEEN ENTEST BIOMEDICAL, INC. AND LINDA BLACK

Agreement
made on March 20, 2017 (“Execution Date”) by and between Linda Black (“Consultant”), a natural person
whose address is ___________and Entest BioMedical Inc.

(“Company”),
a Nevada corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942. Consultant and Company may be referred
to individually as “Party” and collectively as “Parties”.

 

 

It
is agreed as follows:

 

1.
SCOPE OF SERVICES

Consultant
shall advise client on various nominal matters regarding veterinary biotechnology for the Company's wholly owned subsidiary Zander
Therapeutics Inc. "Nominal" is defined as periodic conversations in which Consultant is asked for a referral to an appropriate
researcher on a specific topic or input on research model the company is developing. In the event Consultant is requested to provide
research services, such services will be negotiated separately between Consultant and the Company.

 

2.
TERM

The
Term of this Agreement shall commence on March 20, 2017 and shall expire on March 19, 2018. The term of this Agreement may be
extended by mutual agreement.

 

3.
INDEPENDENT CONTRACTOR

The
Parties are independent contractors. Nothing in this Agreement shall be deemed to constitute a partnership or joint venture between
the Parties or constitute any Party to be the agent of the other Party for any purpose.

 

4.
NON-DISCLOSURE

(a)
All information, whether in oral, written, graphic, electronic or other form, disclosed by the Company to the Consultant shall
be deemed to be “Proprietary Information.” In particular, Proprietary Information includes, without limitation, any
trade secrets, confidential information, ideas, inventions or research and development information; matters of a technical nature,
including technology; notes, products, knowhow, engineering or other data (including test data and data files); specifications,
processes, techniques, formulae or work-in-process; manufacturing, planning or marketing procedures, clinical data and regulatory
strategies or information; accounting, financial or pricing procedures or information, budgets or projections, or personnel or
salary structure/compensation information; information regarding suppliers, clients, customers, employees, contractors, investors
or investigators of the Company, information which has been designated in writing as confidential by the Company; programs, procedures
(including operating procedures), processes, methods, guidelines, policies, proposals or contracts; computer software, data bases
or programming; and any other information which, if divulged to a third party, could have an adverse impact on the Company, or
on any third party to which it owes a confidentiality obligation. In addition, “Proprietary Information” includes
any of the foregoing relating to the past, present or future operations, organization, projects, finances, business interests,
methodology or affairs of any third party to which the Company owes a duty of confidentiality including, without limitation, the
mere fact that the Company is or may be working with or for any client.

 

(b)
The obligations of confidentiality shall not apply to any Proprietary Information that was known by the Consultant at the time
of disclosure to it by such Company, or that is independently developed or discovered by the Consultant after disclosure by such
Company, without the aid, application or use of any item of such Company’s Proprietary Information, as evidenced by written
records; now, or subsequently becomes, through no act or failure to act on the part of the Consultant, generally known or available;
is disclosed to the Consultant by a third party authorized to disclose it; or is required by law or by court or administrative
order to be disclosed; provided, that the Consultant shall have first

given
prompt notice to such Company of such required disclosure.

 

(c)
Consultant shall exercise due care to prevent the unauthorized use or disclosure of the Company’s Proprietary Information,
and shall not, without the Company’s prior written consent, disclose or otherwise make available, directly or indirectly,
any item of the Company’s Proprietary Information to any person or entity other than those employees, independent contractors
or agents of the Consultant (collectively, “Representatives”), to the extent such Representatives reasonably need
to know the same in order to evaluate such Proprietary Information, to participate in the business relationship between the parties,
or to make decisions or render advice in connection therewith. Consultant shall advise its Representatives who have access to
the Company’s Proprietary Information of the confidential and proprietary nature thereof, and agrees that such Representatives
shall be bound by terms of confidentiality and restrictions on use with respect thereto that are at least as restrictive as the
terms of this Agreement.

 

(d)
Consultant shall exercise due care to prevent the unauthorized use or disclosure of the Company’s Proprietary Information,
and shall not, without the Company’s prior written consent, disclose or otherwise make available, directly or indirectly,
any item of the Company’s Proprietary Information to any person or entity other than those employees, independent contractors
or agents of the

Consultant
(collectively, “Representatives”), to the extent such Representatives reasonably need to know the same in order to
participate in any business relationship between the parties, or to make decisions or render advice in connection therewith. Consultant
shall advise its Representatives who have access to the Company’s Proprietary Information of the confidential and proprietary
nature thereof, and agrees that such Representatives shall be bound by terms of confidentiality and restrictions on use with respect
thereto that are at least as restrictive as the terms of this Agreement.

 

(e)
Consultant shall use the Company’s Proprietary Information solely for the purposes of performing his duties pursuant to
this Agreement and shall not make any other use of the Company’s Proprietary Information without the Company’s specific
written authorization.

 

(f)
All Proprietary Information of the Company (including all copies thereof) shall be and at all times remain the property of such
Company, and all non-oral Proprietary Information of the Company which is then in the Consultant’s possession or control
shall be destroyed or returned to the Company promptly upon its request at any time, and in any event, no later than 60 days following
any expiration or termination of this Agreement.

 

(g)
Nothing in this Agreement shall be construed, by implication or otherwise, as a grant of any right or license to trademarks, inventions,
copyrights or patents, as a grant of a license to either Consultant to use any of the Company’s Proprietary Information
except as expressly set forth herein.

 

(h)
The provisions of Section 4 of this Agreement shall survive until such time as all Confidential Information disclosed hereafter
becomes publically known and made generally available through no action or inaction of Consultant.

 

5.
CONSIDERATION

As
consideration of the performance of services pursuant to this Agreement, Consultant shall receive:

 

(1)
Within 15 business days of the execution date of this Agreement Consultant shall be issued 100,000 shares of the Series B Preferred
Stock of the Company (“Compensation Shares”).

 

(2)
Within 30 business days subsequent to the effective date of a Registration Statement filed under the Securities Act of 1933, as
amended, registering common shares of Zander Therapeutics, Inc. (“Zander Registration Statement”) Consultant shall
have the right to exchange up to the total number of the Compensation Shares issued to the Consultant pursuant to the terms and
conditions of this Agreement for an equivalent number of the common shares of Zander Therapeutic, Inc. six months after Zander
Therapeutics Inc. clears a registration statement. This right shall be withdrawn in the event of any breach of the terms and conditions
of this Agreement by the Consultant.

 

(3)
Consultant acknowledges that nothing in this Agreement shall obligate either of the Company or Zander Therapeutics Inc. to register
the common shares of Zander Therapeutics, Inc. under the Securities Act of 1933, as amended.

 

(4)
Consultant acknowledges that, in the event that a Zander Registration Statement is filed with the United States Securities and
Exchange Commission (“SEC”), no assurance is given that the Zander Registration Statement will be declared effective
by the SEC.

 

(5)
Consultant acknowledges that any securities issued pursuant to this Agreement that are not registered pursuant to the Securities
Act of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Securities
Act of 1933, and shall contain the following restrictive legend:

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

 

6.
REPRESENTATIONS AND WARRANTIES OF COMPANY

(a)
Company is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and
has the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent,
approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

(b)
The execution, delivery and performance of this Agreement by Company does not and shall not constitute Company’s breach
of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of
or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument
to which the Company is a party, or by which Company is or may be bound.

 

7.
REPRESENTATIONS AND WARRANTIES OF CONSULTANT

(a)
Consultant has the requisite power and authority to enter into and perform his obligations under this Agreement without the consent,
approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

 

(b)
The execution, delivery and performance of this Agreement by Consultant does not and shall not constitute Consultant’s breach
of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of
or default under any of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument
to which the Consultant is a party, or by which Company is or may be bound.

 

8.
NON-DISPARAGEMENT

Consultant
agrees that Consultant shall not, during the term of this Agreement, disparage the Company, the Company’s products, the
Company’s employees, or members of the Company’s board of directors. For purposes of this Agreement the term “disparage”
shall mean any negative comment, written or oral, about the Company, the Company’s products, the Company’s employees,
or members of the Company’s board of directors. . Nothing set forth in this Agreement shall prohibit or limit in any way
a Party’s right to accurately and honestly respond as required or to cooperate with any valid government, court or regulatory
order or request. The provisions of Section 8 of this Agreement shall survive until that date which is three years subsequent
to the end of the Term of this Agreement.

 

9.
WORK PRODUCT

Consultant
agrees that the Company is the sole and exclusive owner of all intellectual property, including copyrights, trademarks, patents,
inventions, work product and know-how, which may result from any work performed by the Consultant pursuant to this Agreement.
Consultant agrees that Consultant shall, upon request of the Company, execute, acknowledge, deliver and file any and all documents
necessary or useful to vest in the Company all of Consultant’s right, title and interest in and to all intellectual property,
including copyrights, trademarks, patents, inventions, work product and know-how, which may result from any work performed by
the Consultant pursuant to this Agreement. The term "Inventions" means all original works of authorship, developments,
concepts, improvements or trade secrets, whether or not patentable under law, that Consultant may individually or jointly conceive
or develop or reduce to practice, or cause to be conceived or developed or reduced to practice which may result from any work
performed by the Consultant pursuant to this Agreement

 

10.
SPECIFIC PERFORMANCE

Any
breach of this Agreement may result in irreparable damage to Company for which Company will not have an adequate remedy at law.
Accordingly, in addition to any other remedies and damages available, Consultant acknowledges and agrees that Company may immediately
seek enforcement of this Agreement by means of specific performance or injunction, without any requirement to post a bond or other
security.

 

11.
EXECUTION

This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same Agreement
and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood
that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.

 

12.
ENTIRE AGREEMENT

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

 

13.
SEVERABILITY

If
any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefore, and upon so agreeing, shall incorporate
such substitute provision in this Agreement

 

14.
GOVERNING LAW, VENUE, WAIVER OF JURY TRIAL

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their

respective
authorized signatories as of the date first indicated above.

 

CONSULTANT

 

By:/s/Linda
Black

 

Date:
March 21, 2017

 

COMPANY

 

By:
/s/Harry Lander, Ph.D. By:

____________________

Its:
President and CSO

Date:
March 17, 2017June
8, 2017

 

VIA
ELECTRONIC MAIL

 

	 	Re:	Agreement
    to Convert – Series D Preferred Stock;
	 	 	Receipt
    of Warrant;

 

Dear:

 

Reference
is made to the 75 shares of Series D Preferred Stock (the “Preferred Stock”) issued by Pressure BioSciences, Inc.
(the “Company”) to you in November 2011. The Company expects to undertake a 1 for 30 reverse stock split on Monday,
June 5, 2017. Unless the context otherwise requires, all of the numbers reflected herein are represented on a pre-reverse stock
split basis.

 

Our
Current Financing

 

As
you may be aware, the Company is currently in the process of pursuing a public offering of its securities to raise up to $12,500,000
and list its securities onto the NASDAQ Stock Market (the “Offering”). The Company has filed a registration statement
on Form S-1 related to the Offering which is being led by Joseph Gunnar & Co (the “Underwriter”). The registration
statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective.
These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
A copy of the preliminary offering prospectus and registration statement related to the Offering can be found at www.sec.gov
and may be obtained by writing to the Company at the address below, attention: CEO. The Company believes that attaining and
maintaining the listing of our shares of common stock, par value $0.01 per share (the “Common Stock”), on the NASDAQ
Stock Market is in the best interests of our Company and its stockholders. The Company is therefore contacting you and other holders
of debt and preferred stock to request that holders convert their Preferred Stock into Common Stock.

 

What
We Need From You

 

By
executing and delivering this letter, you hereby agree:

 

	 	I.	That
    on May 10, 2017 you converted 75 shares of Preferred Stock into 187,500 restricted shares of Common Stock.
	 	 	 
	 	II.	That
    upon the conversion of the 75 shares of Preferred Stock into 187,500 restricted shares of Common Stock, PBI agreed to issue
    you an additional 112,500 restricted shares of Common Stock and a new warrant (the “New Warrant”) to purchase
    298,328 shares of Common Stock of the Company with $0.28 exercise price. The terms of the New Warrant will be substantially
    similar to the warrants being included in the Offering, except such New Warrants will have a $0.28 exercise price, will be
    restricted securities, and will not trade on NASDAQ. For the sake of clarity, you understand that the New Warrants will not
    contain a “Subsequent Equity Sales” provision that lowers the exercise price of the New Warrants upon any future
    dilutive issuance of shares of Common Stock.

 

 

 

    	 	 	 

    	 

    

 

Upon
the triggering of Automatic Conversion, the Company shall send
you: (i) prompt written notice (the “Automatic Conversion
Notice”) specifying the date upon which such conversion was effective
(the “Effective Date”); and (ii) the New Warrants. The Automatic Conversion
Notice will also contain instructions on surrendering to the Company your original Preferred Stock certificates; provided, however,
the Automatic Conversion shall be effective on the Effective Date whether or not you surrender the Preferred Stock certificates,
which shall be null and void on the Effective Date.

 

By
executing and delivering this letter, you hereby also agree to the following lock-up conditions:

 

	 	a.	That
    for a period of 90 days beginning on the Effective Date (the “Lock-Up Period”),
    you will not, without the prior written consent of the Underwriter, (1) offer, pledge, sell, contract to sell, grant, lend,
    or otherwise transfer or dispose of, directly or indirectly, any shares of the Common Stock you currently own or will own
    including those hereafter acquired by you or with respect to which you hereafter acquire the power of disposition (collectively,
    the “Lock-Up Securities”); (2) enter into any swap or other arrangement that transfers to another, in whole or
    in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in
    clause (1) above or this clause (2) is to be settled by delivery of Lock-Up Securities, in cash or otherwise; (3) make any
    demand for or exercise any right with respect to the registration of any Lock-Up Securities; or (4) publicly disclose the
    intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement
    relating to any Lock-Up Securities. Notwithstanding the foregoing, and subject to the conditions below, you may transfer Lock-Up
    Securities without the prior written consent of the Underwriter in connection with (a) transfers of Lock-Up Securities as
    a bona fide gift, by will or intestacy or to a family member or trust for the benefit of a family member (for purposes of
    this Letter Agreement, “family member” means any relationship by blood, marriage or adoption, not more remote
    than first cousin); (b) transfers of Lock-Up Securities to a charity or educational institution; (c) transfers of Lock-Up
    Securities pursuant to a bona fide third party tender offer made to all holders of the Common Stock, merger, consolidation
    or other similar transaction involving a change of control (as defined below) of the Company, including voting in favor of
    any such transaction or taking any other action in connection with such transaction, provided that in the event that such
    merger, tender offer or other transaction is not completed, the Lock-Up Securities shall remain subject to the restrictions
    set forth herein; or (d) transfers of Lock-Up Securities in the case of a “forced conversion” by the Company.
    In the case of any transfer pursuant to the foregoing clauses (a) or (b), (i) any such transfer shall not involve a disposition
    for value, (ii) each transferee shall sign and deliver to the Underwriter a lock up agreement substantially in the form of
    the lock-up provisions of this Letter Agreement and (iii) no filing under Section 16(a) of the Securities Exchange Act of
    1934, as amended (the “Exchange Act”) shall be required or shall be voluntarily made. You also agree and consent
    to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of your
    Lock-Up Securities except in compliance with the lock-up provisions of this Letter Agreement. For purposes of clause (d) above,
    “change of control” shall mean the consummation of any bona fide third party tender offer, merger, purchase, consolidation
    or other similar transaction the result of which is that any “person” (as defined in Section 13(d)(3) of the Securities
    Exchange Act of 1934, as amended (the “Exchange Act”)), or group of persons, becomes the beneficial owner (as
    defined in Rules 13d-3 and 13d-5 of the Exchange Act) of a majority of total voting power of the voting stock of the Company.
    

 

 

    	 	 	 

    	 

    

 

	 	b.	If
    (i) during the last 17 days of the Lock-Up Period, the Company issues an earnings release or material news or a material event
    relating to the Company occurs, or (ii) prior to the expiration of the Lock-Up Period, the Company announces that it will
    release earnings results or becomes aware that material news or a material event will occur during the 16-day period beginning
    on the last day of the Lock-Up Period, the restrictions imposed by the lock-up provisions of this Letter Agreement shall continue
    to apply until the expiration of the 18-day period beginning on the issuance of the earnings release or the occurrence of
    such material news or material event, as applicable, unless the Underwriter waives, in writing, such extension.
	 	 	 
	 	c.	You
    agree that, prior to engaging in any transaction or taking any other action that is subject to the terms of the lock-up provisions
    of this Letter Agreement during the initial Lock-Up Period and including the 34th day following the expiration
    of the initial Lock-Up Period, you will give notice thereof to the Company and will not consummate any such transaction or
    take any such action unless you have received written confirmation from the Company that the Lock-Up Period (as may have been
    extended pursuant to the previous paragraph) has expired. 
	 	 	 
	 	d.	No
    portion of the lock-up provisions of this Letter Agreement shall be deemed to restrict or prohibit the exercise, exchange
    or conversion by you of any securities exercisable or exchangeable for or convertible into the Lock-Up Securities, as applicable;
    provided that you do not transfer the Lock-Up Securities acquired on such exercise, exchange or conversion during the Lock-Up
    Period, unless otherwise permitted pursuant to the terms of the lock-up provisions of this Letter Agreement. In addition,
    no provision herein shall be deemed to restrict or prohibit the entry into or modification of a so-called “10b5-1”
    plan at any time (other than the entry into or modification of such a plan in such a manner as to cause the sale of any Lock-Up
    Securities within the Lock-Up Period).

 

 

    	 	 	 

    	 

    

 

	 	e.	You
    understand that the lock-up provisions of this Letter Agreement are irrevocable and shall be binding upon your heirs, legal
    representatives, successors and assigns.

 

By
your agreement and acknowledgment below, this Letter Agreement shall serve as written confirmation that:

 

	 	1.	You
    agree to the terms of the Automatic Conversion and the New Warrants.
	 	 	 
	 	2.	Upon
    the date of the Automatic Conversion, the New Warrants shall be deemed issued as described herein irrespective of your physical
    receipt of same. 
	 	 	 
	 	3.	You
    acknowledge and agree that upon the Automatic Conversion the Preferred Stock shall be cancelled. 

 

By
signing below, this Letter Agreement shall serve as written confirmation that you have reviewed this Letter Agreement (and consulted
with your legal and tax advisors to the extent you deemed necessary) and agree to the terms and conditions of the Automatic Conversion
and the New Warrants as described herein. Upon the Effective Date of such conversion, you understand that you will be releasing
and discharging the Company and its affiliates from any and all obligations and duties that such persons may have to you with
respect to Preferred Stock. Notwithstanding anything contained herein, in the event the Offering is not consummated on or before
December 31, 2017, this Letter Agreement will terminate and shall be of no further force and effect.

 

 

 

    	 	 	 

    	 

    

 

This
Letter Agreement contains the entire understanding between and among the parties and supersedes any prior understandings and agreements
among them respecting the subject matter of this Letter Agreement. In addition, you hereby represent that you meet the requirements
of at least one of the suitability standards for an “accredited investor” as that term is defined in Regulation D
promulgated under the Securities Act of 1933, as amended and that you have had the opportunity to obtain any additional information,
to the extent the Company has such information in its possession or could acquire it without unreasonable effort or expense, necessary
in connection with the matters set forth in this Letter Agreement including, without limitation, information concerning the financial
condition, results of operations, capitalization and business of the Company deemed relevant by you or your advisors, if any,
and all such requested information, to the extent the Company had such information in its possession or could acquire it without
unreasonable effort or expense, has been provided to your full satisfaction. This Letter Agreement shall be governed by and construed
in accordance with the laws of the Commonwealth of Massachusetts without regard to choice of law principles. This Letter Agreement
may be executed in any number of counterparts, each of which shall be an original but all of which together shall constitute one
and the same instrument. In case any provision of this Letter Agreement shall be held to be invalid, illegal or unenforceable,
such provision shall be severable from the rest of this Letter Agreement, and the validity legality and enforceability of the
remaining provisions shall not in any way be affected or impaired thereby.

 

This
letter evidences waiver by the undersigned with respect to any and all defaults or events of default by the Company with respect
to any failure by the Company to comply with any covenants contained in the Preferred Stock or the transaction documents signed
in connection with the issuance thereof.

 

The
parties hereby consent and agree that if this Letter Agreement shall at any time be deemed by the parties for any reason insufficient,
in whole or in part, to carry out the true intent and spirit hereof or thereof, the parties will execute or cause to be executed
such other and further assurances and documents as in the reasonable opinion of the parties may be reasonably required in order
more effectively to accomplish the purposes of this Letter Agreement.

 

***REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK***

 

 

    	 	 	 

    	 

    

 

Please
indicate confirmation of the terms provided herein by executing and returning this letter in the space provided below.

 

	 	Very
    truly yours,
	 	 
	 	PRESSURE
    BIOSCIENCES, INC.
	 	 	 
	 	By:	    
	 	Name:	Richard
    T. Schumacher
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	Date:	_________________,2017

 

	ACCEPTED
    AND AGREED:	 	 
	 	 	 
	INVESTOR	 	 
	 	 	 
	 	 	 
	 	 	 
	Date:
    ____________, 2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00272-of-00352.parquet"}]]